New CEO Appointment Puts Pressure on Advanced Health Intelligence’s Commercial Success

Leadership Change at a Pivotal Moment

Advanced Health Intelligence Ltd (AHI) has announced the appointment of Dylan Garnett as its new Chief Executive Officer, effective immediately. Garnett steps into the role at a critical juncture as AHI advances through its ASX reinstatement process and sharpens its focus on commercialisation and sustainable revenue growth.

Garnett brings a wealth of experience spanning over 25 years across healthcare, insurance, and technology sectors. His prior leadership roles include CEO and Managing Director of Metropolitan Health in South Africa, COO/CCO of LifeQ, a global leader in computational physiology, and co-founder of Vertica Health, which AHI acquired in 2022. This diverse background equips him with a unique blend of scientific insight and commercial acumen.

Driving Commercialisation and Market Expansion

Since joining AHI as Chief Innovation Officer following the Vertica Health acquisition, Garnett has been instrumental in product development and expanding market reach. His appointment as CEO underscores AHI’s strategic shift from innovation to execution, aiming to translate its cutting-edge smartphone-based health risk assessment technology into tangible revenue streams.

AHI’s technology leverages smartphone sensors to enable users to perform comprehensive health assessments, identifying risk markers for conditions such as cardiovascular disease, diabetes, and skin cancers. Garnett’s experience at LifeQ, where he helped commercialise advanced health modelling technologies powering global wearable devices, aligns closely with AHI’s mission to embed validated digital health insights into healthcare, insurance, and corporate wellness ecosystems.

Aligning Leadership Incentives with Shareholder Value

Garnett’s remuneration package includes a fixed base salary of US$240,000, benchmarked against comparable ASX-listed health tech companies. Importantly, AHI is finalising a performance securities package designed to align his incentives with shareholder outcomes, tying rewards to revenue growth, share price performance, and commercial milestones. This approach signals a clear commitment to value creation and disciplined execution.

The appointment also marks the departure of outgoing CEO Scott Montgomery, who has resigned as an Executive Director. The company expressed gratitude for Montgomery’s contributions during his tenure.

Looking Ahead

With Garnett at the helm, AHI aims to streamline operations, reduce costs, and deepen market penetration. His proven track record in scaling health technology ventures and forging strategic partnerships positions the company to accelerate its commercial trajectory. The board’s endorsement reflects confidence that Garnett’s leadership will drive stronger execution and sustainable growth, enhancing shareholder value as AHI navigates its next chapter.